Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

AKBA : 17.57 (+0.29%)
BMRN : 94.95 (+1.64%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

AKBA : 17.57 (+0.29%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
GTXI : 8.76 (+0.23%)
Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

RARE : 52.16 (-0.69%)
AKBA : 17.57 (+0.29%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Stocks Under Scanner in the Biotech Space -- Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics

If you want a Stock Review on ACOR, ADXS, XBIT, or AKBA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, September 08, 2017, the NASDAQ...

ADXS : 4.57 (-3.38%)
AKBA : 17.57 (+0.29%)
ACOR : 23.45 (-0.64%)
XBIT : 4.19 (-4.56%)
BioMarin Presents Interim Data on BMN 250 from Phase I/II

BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

AKBA : 17.57 (+0.29%)
BMRN : 94.95 (+1.64%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

AKBA : 17.57 (+0.29%)
Akebia to Present at Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 48.22 (-0.08%)
AKBA : 17.57 (+0.29%)
FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

AKBA : 17.57 (+0.29%)
ACOR : 23.45 (-0.64%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Strength Seen in Catalent (CTLT): Stock Soars 13.9%

Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

CTLT : 40.76 (+1.29%)
AKBA : 17.57 (+0.29%)
Adamas Pharmaceu has the Best Relative Performance in the Biotechnology Industry (ADMS, ACOR, ESPR, AKBA, EPZM)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ESPR : 49.31 (-0.12%)
ADMS : 21.37 (+0.23%)
AKBA : 17.57 (+0.29%)
ACOR : 23.45 (-0.64%)
EPZM : 16.95 (-9.36%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Immunogen Inc (IMGN, MDXG, PGNX, ALDR, AKBA)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

MDXG : 12.63 (+2.93%)
PGNX : 6.96 (unch)
ALDR : 10.85 (+3.83%)
AKBA : 17.57 (+0.29%)
IMGN : 6.55 (+0.77%)
Akebia Announces Second Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 17.57 (+0.29%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 17.57 (+0.29%)
Shares of AKBA Up 39.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 7 months, Akebia Therapeut has returned 39.58% as of today's recent price of $14.00....

AKBA : 17.57 (+0.29%)
Akebia Therapeut Has Returned 44.2% Since SmarTrend Recommendation (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 7 months, Akebia Therapeut has returned 44.17% as of today's recent price of $14.46....

AKBA : 17.57 (+0.29%)
Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 48.22 (-0.08%)
AKBA : 17.57 (+0.29%)
Akebia Announces Pricing of Public Offering of Common Stock

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 48.22 (-0.08%)
AKBA : 17.57 (+0.29%)
Uptrend Call Working As Akebia Therapeut Stock Rises 61.7% (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 6 months, Akebia Therapeut has returned 61.71% as of today's recent price of $16.22....

AKBA : 17.57 (+0.29%)
Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor...

AKBA : 17.57 (+0.29%)
Technical Insights on Biotech Stocks -- Soligenix, Sorrento Therapeutics, Alcobra, and Akebia Therapeutics

On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.39%; the Dow Jones Industrial Average edged 0.04% higher; and the S&P 500 was up 0.03%....

SRNE : 1.80 (unch)
ADHD : 1.12 (+1.82%)
AKBA : 17.57 (+0.29%)
SNGX : 2.27 (+3.18%)
SNGXD : 4.1500 (-5.68%)

Van Meerten Stock Picks

5 Great Mid Caps
Today I wanted to find 5 Mid Cap stocks that had a high gain over the last year and continue to have current momentum.
DAN +0.41 , IPGP +4.16 , TEX -0.46 , NVR +29.06 , TTWO +1.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.14% ) this morning are down -0.09% on heightened North Korean tensions after North Korean President Kim Jong Un promised the "highest level of hardline" countermeasures against the U.S.... Read More

Chart of the Day

Chart of the Day

Fiat Chrysler Automobiles (FCAU) is the Barchart Chart of the Day.  The international auto producer has a Trend Spotter buy signal, a Weighted Alpha of 190.70+ and gained 174.92% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures settled Friday with 2 to 3 1/2 cent gains, as Dec was 1 1/4 cent lower on the week. Rains over the next week could slow corn harvest in most of the WCB. Next Friday at 11:00 a.m. will be the release of the Sept 1 Grain Stocks report. The...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.